Log In
BCIQ
Print this Print this
 

Aviptadil (DK-1000)

  Manage Alerts
Collapse Summary General Information
Company Relief Therapeutics Holding AG
DescriptionSynthetic peptide-based vasoactive intestinal polypeptide (VIP)
Molecular Target Vasoactive intestinal peptide receptor 1 (VPAC1) ; Vasoactive intestinal peptide receptor 2 (VPAC2)
Mechanism of ActionImmune modulation
Therapeutic ModalityPeptide

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/15/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today